Rogier Mous
Impact in
-
- Lymphoma Diagnosis and Treatment
- Genetics top 5%
- Chronic Lymphocytic Leukemia Research
Papers in
- Genetics 22
- Chronic Lymphocytic Leukemia Research 21
-
- Lymphoma Diagnosis and Treatment 18
- Co-authors
- Sandra van Wetering (1 shared paper)Ingrid Lommerse (1 shared paper)Peter L. Hordijk (1 shared paper)Jean Paul ten Klooster (1 shared paper)Jaap D. van Buul (1 shared paper)Erik Mul (1 shared paper)Martine E.D. Chamuleau (13 shared papers)Jaap Jan Zwaginga (1 shared paper)
- Journals
- Blood (7 papers)Journal of Clinical Oncology (4 papers)HemaSphere (3 papers)American Journal of Hematology (2 papers)Hematological Oncology (2 papers)
- Partner nations
- NetherlandsUnited StatesUnited Kingdom
In The Last Decade
Rogier Mous
32 papers receiving 713 citations
Rogier Mous's Hit Papers
Peers
Comparison fields: 5 of 71
- Pathology and Forensic Medicine 308
- Genetics 174
- Oncology 392
- Immunology and Allergy 86
- Immunology 245
Countries citing papers authored by Rogier Mous
This map shows the geographic impact of Rogier Mous's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Rogier Mous with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Rogier Mous more than expected).
Fields of papers citing papers by Rogier Mous
This network shows the impact of papers produced by Rogier Mous. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Rogier Mous. The network helps show where Rogier Mous may publish in the future.
Co-authors
The 25 scholars most cited alongside Rogier Mous, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
Showing the 20 most-cited of 35 papers — load more, or switch the sort, to bring in the rest.
| # | Work | ||
|---|---|---|---|
| 1 | Dose escalation of subcutaneous epcoritamab in patients with relapsed or refractory B-cell non-Hodgkin lymphoma: an open-label, phase 1/2 study Hit paper breakdown → | 2021 | 212 |
| 2 | 2003 | 187 | |
| 3 | 2009 | 91 | |
| 4 | 2020 | 42 | |
| 5 | 2018 | 21 | |
| 6 | 2020 | 19 | |
| 7 | 2006 | 17 | |
| 8 | 2021 | 16 | |
| 9 | 2019 | 16 | |
| 10 | 2021 | 14 | |
| 11 | 2023 | 11 | |
| 12 | 2018 | 9 | |
| 13 | 2023 | 8 | |
| 14 | 2018 | 8 | |
| 15 | 2022 | 6 | |
| 16 | 2017 | 6 | |
| 17 | 2022 | 5 | |
| 18 | 2021 | 5 | |
| 19 | 2022 | 4 | |
| 20 | 2008 | 3 |
About Rogier Mous
Rogier Mous is a scholar working on Genetics, Pathology and Forensic Medicine, Oncology, Immunology and Hematology, having authored 35 papers that have together received 723 indexed citations. Recurring topics across this work include Chronic Lymphocytic Leukemia Research (21 papers), Lymphoma Diagnosis and Treatment (18 papers), CAR-T cell therapy research (11 papers), Monoclonal and Polyclonal Antibodies Research (5 papers), Protein Degradation and Inhibitors (4 papers), Immune Cell Function and Interaction (4 papers), Acute Myeloid Leukemia Research (3 papers) and Biosimilars and Bioanalytical Methods (3 papers). The work is most often cited by research in Pathology and Forensic Medicine (308 citations), Genetics (174 citations), Oncology (392 citations), Immunology and Allergy (86 citations) and Immunology (245 citations). Rogier Mous has collaborated with scholars based in Netherlands, United States and United Kingdom. Frequent co-authors include Sandra van Wetering, Ingrid Lommerse, Peter L. Hordijk, Jean Paul ten Klooster, Jaap D. van Buul, Erik Mul, Martine E.D. Chamuleau, Jaap Jan Zwaginga, Kim Linton and Pieternella J. Lugtenburg. Their work appears in journals such as Blood, Journal of Clinical Oncology, HemaSphere, American Journal of Hematology and Hematological Oncology.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.